Adagrasib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200 mg
Reference Brands: Krazati (USA)
Category: Oncology Cancer Care
Adagrasib is a small-molecule inhibitor that selectively binds to the mutant KRAS G12C protein, preventing cancer cell growth and survival. It is primarily used in certain non-small cell lung cancers (NSCLC) and colorectal cancers with the KRAS G12C mutation. Adagrasib is available in Tablets and strengths such as 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Adagrasib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Adagrasib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Adagrasib is used to treat certain cancers in adult patients whose tumors carry the KRAS G12C mutation. It is approved for advanced or metastatic Non‑Small Cell Lung Cancer (NSCLC) after prior therapy, and in combination with Cetuximab for advanced or metastatic Colorectal Cancer (CRC) with KRAS G12C mutation in patients who have received prior chemotherapy.
Adagrasib is a small‑molecule drug designed to irreversibly bind to the mutant KRAS G12C protein, inhibiting its function and blocking tumor-promoting signaling. Its chemical formula is C₃₂H₃₅ClFN₇O₂, and it is formulated with excipients suitable for oral administration.
The trade name for Adagrasib is Krazati.
Adagrasib (Krazati) was developed by Mirati Therapeutics and is part of Bristol Myers Squibb’s oncology portfolio. Generic production is not widely available yet.
The generic name is adagrasib.
The brand name is Krazati.
Adagrasib is manufactured under GMP conditions in regulated facilities operated by Mirati Therapeutics and Bristol Myers Squibb for global distribution.a
Related Products
Gemtuzumab Ozogamicin
Strength:
4.5 mg
Form: Injection
Reference Brands: Mylotarg (USA)
View Details
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
